Articles tagged with Gliomas
A new study identifies a crucial gene in pediatric high-grade glioma, which may lead to the development of more effective drugs. The research found that the PDGFRA gene is unusually active in childhood cancer and is likely to be an important drug target.
Researchers at Agios Pharmaceuticals have discovered that the mutated IDH1 gene produces a metabolite called 2-hydroxyglutarate, which contributes to the formation and progression of gliomas. This finding validates cancer metabolism as an approach to identify new ways to treat cancer.
Researchers found that physical activity in adolescence was associated with a 36% lower risk of glioma, the most common type of brain cancer. Participants who were obese during adolescence had an increased risk of glioma, while height was linked to twice the risk.
Patients who received radiotherapy for low-grade glioma brain tumors showed significant cognitive decline compared to those who did not receive treatment. The study found that attentional functioning, executive functioning, and information processing speed were lower in patients given radiotherapy. Deferring treatment or using modern r...
A large-scale study has identified genetic variations across five genes as risk factors for the development of gliomas, the most frequent type of brain tumor. The study found that individuals with certain variations have a higher risk of developing glioma, with those with eight or more variations having a three-fold increased risk.
Researchers found hypofractionated stereotactic radiotherapy improved symptoms and survival time in patients with recurrent low-grade glioma. The treatment was well-tolerated and allowed patients to complete the full course of therapy.
Scientists at Duke University Medical Center and Johns Hopkins University have identified two genes with potential as therapeutic targets for malignant glioma, a deadly class of brain tumors. IDH1 mutations were found in over 70% of astrocytomas and olidgodendrogliomas, associated with longer survival times.
Scientists have identified two gene mutations, IDH1 and IDH2, linked to nearly three-quarters of gliomas, a type of brain cancer. These mutations are associated with longer survival rates in patients with certain types of gliomas. Further research may lead to more precise diagnoses and treatments.
Researchers at the Salk Institute used fruit flies as a model to study gliomas, the most common malignant brain tumors. They found that activating specific signaling pathways in the fly brains resulted in tumor-like growths, mimicking human disease.
Patients with low-grade gliomas who underwent aggressive surgeries were free of tumor recurrence an average of 15 years after diagnosis. Radiation therapy significantly extended their survival time, with patients living up to six years without tumor recurrence.
A veterinary neurologist is studying gliomas in dogs and people to develop more precisely targeted treatments. Researchers are using canine models to identify molecular similarities between human and animal gliomas.
Researchers used perfusion MRI to track changes in blood volume in patients with low-grade gliomas, finding that increased rCBV is an indicator of future malignant transformation. The study suggests that significant changes in rCBV represent an early warning sign of impending malignant transformation.
Researchers found a new chemotherapy regimen of irinotecan and cisplatin to be effective in treating childhood brainstem gliomas, with all six children showing significant tumor reduction. While the disease eventually progressed in three children, this is a promising breakthrough for a previously difficult-to-treat cancer.
Researchers discovered the p75NTR receptor plays a key role in glioma invasion, with expression sufficient to induce aggressive tumor growth. This finding highlights a previously unknown function of the receptor and suggests it may be a novel therapeutic target.
A clinical trial at UCSF Brain Tumor Research Center has shown promising results using the vitespen vaccine to stimulate the immune system to attack tumor cells. The vaccine, made from a patient's own tumor, induced a tumor-specific immune response in all 12 study patients.
Researchers have developed a new approach to treating gliomas, deadly brain tumors, by delivering radioactive iodine using a man-made version of scorpion venom as a carrier. The treatment targets glioma cells without affecting neighboring tissue or body organs and has shown promise in Phase I clinical trials.
Gliadel Wafer demonstrates long-term survival benefit for patients with high-grade malignant glioma, increasing median survival to 13.9 months from 11.6 months. The treatment also shows a significant reduction in risk of death over the study period, with a 27% lower risk compared to placebo.
A phase I study found that glioma patients who responded to erlotinib treatment had higher levels of EGFR expression and amplification. The level of phosphorylated PKB/Akt was also associated with response to erlotinib, as well as time to progression.
The study found significant variations in treatment practices for patients with malignant glioma, including differences in the use of radiation therapy, chemotherapy, and antidepressants. These variations were associated with differences in survival rates, highlighting the need for further investigation and potential improvements to tr...
Researchers found that new blood vessels and immune system cells are essential to tumor formation, making them promising drug targets; however, brain images used for diagnosis may not be informative.
Researchers at Cedars-Sinai Medical Center have discovered a mechanism by which brain tumors can evade the immune system, leading to impaired cellular immunity in patients with glioma. By blocking COX-2 expression, the study found that tumor-killing T cell responses can be restored, offering new potential treatments for brain tumors.
Cedars-Sinai researchers found that laminin-8 expression is linked to tumor aggressiveness and patient outcomes. High levels of laminin-8 are associated with shorter survival times and increased risk of tumor recurrence.
Researchers found that blocking laminin-8 gene expression significantly reduced glioma cells' ability to invade neighboring tissue. The study supports the hypothesis that laminin-8 is involved in tumor spread and suggests a potential target for intervention strategies.
A large-scale study of 560 patients with malignant gliomas suggests that surgical resection is a critical factor in improving survival rates and quality of life. The study found that younger, more active patients tend to benefit more from aggressive treatment, while age and overall health also play significant roles.
Researchers found that intracranial gliomas damage the thymus, weakening T cells and preventing a large-scale attack on the tumor. The study suggests that glucocorticoids produced by the adrenal glands contribute to this effect, and highlights the importance of recent thymic emigrant T cells in anti-glioma immunity.
A study by the University of Texas M. D. Anderson Cancer Center reveals a strong correlation between the loss of AP-2( transcription factor and the progression of different human gliomas. The findings suggest that this gene acts as a tumor suppressor, controlling various genes involved in cell proliferation and invasion.
Systematic review and meta-analysis of 12 randomised trials shows a 6% increase in one-year survival for patients receiving chemotherapy with radiotherapy compared to those receiving radiotherapy alone. Patients also experience a two-month improvement in average survival time.
Researchers used genetic tools to create mouse models of gliomas, revealing that the timing of PDGF expression can determine glioma characteristics. These findings suggest that drugs promoting glial cell differentiation may be effective for low-grade gliomas.
Scientists at Cedars-Sinai Medical Center used gene array technology to analyze thousands of genes in malignant brain tumor samples. They identified a critical step in the development of glioblastoma multiforme, which may improve patient prognosis and lead to effective therapies.